RyboDyn Inc.
Imad Ajjawi, PhD, MBA, is a seasoned entrepreneur and executive with extensive experience in the biotechnology and pharmaceutical industries. Currently serving as Co-Founder and CEO of RyboDyn Inc. since June 2024, Imad focuses on developing new immunotherapies targeting the dark proteome. Previously, from January 2021 to April 2024, Imad was the VP of Business Development at Absci, where responsibilities included driving business growth and forming strategic partnerships. As Co-Founder and Chief Business Officer of Denovium Inc., acquired by Absci, Imad pioneered AI methods to enhance biopharma innovation. Imad also co-founded Glöbier, known for launching the world's first glow-in-the-dark beer. Other notable roles include Senior Business Development Manager at Synthetic Genomics, Market Analyst Consultant at Locana, and Technology Innovation Consultant at Scripps Institution of Oceanography. Imad's academic credentials include a PhD in Biochemistry from the University of Nevada, Reno, and an MBA from the Rady School of Management at UC San Diego.
This person is not in any teams
RyboDyn Inc.
RyboDyn, Inc. is targeting the dark proteome to make new immunotherapies. We are unlocking and validating previously undiscovered, disease-specific targets that will impact the treatment of cancer and autoimmune diseases by driving a new wave of targeted therapeutics. Our "targets-to-assets" therapeutics development program is supported by a scalable, in-house platform for lead discovery and optimization. We aim to deliver first-in-class assets that recognize these targets for treating solid tumors and diseases lacking effective treatment options.